Athira Pharma Inc, a clinical-stage company dedicated to developing therapies for Alzheimer's and Parkinson's, announced yesterday that it has named Mark Litton, PhD, MBA as its new chief operating officer.
Dr Litton has more than two decades of life sciences experience covering a breadth of responsibilities and achievements. He is co-founder of Alder BioPharmaceuticals, where he served as chief business officer and treasurer from 2004 to 2018. Prior to co-founding Alder BioPharmaceuticals, Dr Litton's experience spans executive leadership positions including vice president of Business Development at Celltech Group, where he was responsible for securing, commercialising, and partnering numerous novel discoveries and therapeutic programs, vice president of Business Development at Chiroscience Group plc, and manager of Business Development for Ribozyme.
Dr Litton holds a PhD in Immunology from Stockholm University, an MBA from Santa Clara University, and a BS in Biochemistry from the University of California, Santa Cruz.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer